Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT – Get Rating) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 32,900 shares, a decline of 31.9% from the July 15th total of 48,300 shares. Based on an average daily volume of 49,200 shares, the short-interest ratio is presently 0.7 days.

Opiant Pharmaceuticals Price Performance

Opiant Pharmaceuticals stock traded up $0.90 during midday trading on Friday, reaching $13.48. The company's stock had a trading volume of 31,822 shares, compared to its average volume of 17,959. The stock has a market cap of $68.48 million, a PE ratio of -3.31 and a beta of 0.52. The company has a current ratio of 8.72, a quick ratio of 8.72 and a debt-to-equity ratio of 0.35. Opiant Pharmaceuticals has a 52 week low of $7.34 and a 52 week high of $37.71. The business has a 50-day moving average price of $11.52 and a 200-day moving average price of $18.20.

Opiant Pharmaceuticals (NASDAQ:OPNT – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The technology company reported ($2.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($1.68). Opiant Pharmaceuticals had a negative net margin of 51.18% and a negative return on equity of 46.15%. The company had revenue of $4.47 million for the quarter, compared to the consensus estimate of $7.13 million. During the same period last year, the firm posted ($0.66) earnings per share. On average, sell-side analysts predict that Opiant Pharmaceuticals will post -6.21 EPS for the current year.

Wall Street Analyst Weigh In

Insider Buying and Selling at Opiant Pharmaceuticals

In related news, Director Michael Sinclair sold 9,736 shares of the business's stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $13.88, for a total value of $135,135.68. Following the completion of the sale, the director now directly owns 59,484 shares in the company, valued at $825,637.92. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, Director Michael Sinclair sold 9,736 shares of the business's stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $13.88, for a total value of $135,135.68. Following the completion of the transaction, the director now owns 59,484 shares of the company's stock, valued at $825,637.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Craig A. Collard acquired 4,037 shares of the business's stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average cost of $10.94 per share, with a total value of $44,164.78. Following the transaction, the director now directly owns 53,822 shares of the company's stock, valued at $588,812.68. The disclosure for this purchase can be found here. Insiders sold 23,751 shares of company stock valued at $304,412 in the last quarter. Company insiders own 25.15% of the company's stock.

Institutional Trading of Opiant Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hillsdale Investment Management Inc. bought a new stake in shares of Opiant Pharmaceuticals during the fourth quarter worth about $108,000. JPMorgan Chase & Co. grew its holdings in Opiant Pharmaceuticals by 10.7% during the 1st quarter. JPMorgan Chase & Co. now owns 7,466 shares of the technology company's stock worth $160,000 after acquiring an additional 723 shares during the last quarter. Advisor Group Holdings Inc. increased its position in Opiant Pharmaceuticals by 28.5% in the 4th quarter. Advisor Group Holdings Inc. now owns 8,125 shares of the technology company's stock valued at $273,000 after acquiring an additional 1,800 shares during the period. State Street Corp raised its stake in shares of Opiant Pharmaceuticals by 10.7% during the first quarter. State Street Corp now owns 13,285 shares of the technology company's stock valued at $285,000 after acquiring an additional 1,285 shares during the last quarter. Finally, Mariner LLC acquired a new position in shares of Opiant Pharmaceuticals during the first quarter worth $290,000. Institutional investors own 27.93% of the company's stock.

About Opiant Pharmaceuticals

(Get Rating)

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.

Recommended Stories

• Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
• MarketBeat: Week in Review 8/8 – 8/12
• 2 Important Retail Stock Battles to Watch
• What Is WallStreetBets and What Stocks Are They Targeting?
• Institutions And Analysts Propel Jack In The Box Higher
• Can You Guess Which EV Stock Is Beating Tesla ?

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.